Advertisement
UK markets close in 1 hour 49 minutes
  • FTSE 100

    8,150.21
    -17.16 (-0.21%)
     
  • FTSE 250

    21,036.22
    -55.27 (-0.26%)
     
  • AIM

    778.47
    -1.70 (-0.22%)
     
  • GBP/EUR

    1.1907
    +0.0019 (+0.16%)
     
  • GBP/USD

    1.2933
    +0.0024 (+0.18%)
     
  • Bitcoin GBP

    51,684.94
    +191.23 (+0.37%)
     
  • CMC Crypto 200

    1,374.25
    +8.36 (+0.61%)
     
  • S&P 500

    5,498.13
    -57.61 (-1.04%)
     
  • DOW

    40,228.02
    -130.07 (-0.32%)
     
  • CRUDE OIL

    77.70
    +0.74 (+0.96%)
     
  • GOLD FUTURES

    2,418.90
    +11.60 (+0.48%)
     
  • NIKKEI 225

    39,154.85
    -439.54 (-1.11%)
     
  • HANG SENG

    17,311.05
    -158.31 (-0.91%)
     
  • DAX

    18,402.11
    -155.59 (-0.84%)
     
  • CAC 40

    7,523.76
    -74.87 (-0.99%)
     

Vericel to Present at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024

Vericel Corporation
Vericel Corporation

CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will participate in a fireside chat at the Leerink Partners Healthcare Crossroads Conference at 9:40 a.m. ET on Wednesday, May 29, 2024.

A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation

Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid® (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns. For more information, please visit www.vcel.com.

ADVERTISEMENT

Epicel and MACI are registered trademarks of Vericel Corporation. NexoBrid is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2024 Vericel Corporation. All rights reserved.

Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411

Media Contact: 
Julie Downs
media@vcel.com